Immunotherapy in NK/T-Cell Lymphoma: Mechanisms, Clinical Evidence, Resistance, and Emerging Multimodal Strategies
Immune checkpoint drugs show real activity in rare NK/T-cell lymphoma, though resistance is common—spurring development of combination strategies and specialized cell therapies.
This review comprehensively evaluates immunotherapy approaches in NK/T-cell lymphoma — a rare, EBV-driven, chemoresistant lymphoma — finding that PD-1/PD-L1 inhibitors show clinically meaningful activity but resistance is common and driven by complex EBV-TIME interactions. Emerging multimodal strategies including EBV-specific CTLs, dual checkpoint blockade, and CAR-T platforms represent an active area of development for this rare, high-unmet-need entity.
What the study was
- Study design
- Narrative review
- Population
- NK/T-cell lymphoma patients
- Category
- Treatment Innovation
- Maturity
- Exploratory
- Journal
- Cancers (Basel)
Why it surfaced
Important rare lymphoma topic with high unmet need; review format without primary trial data limits score.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.